Literature DB >> 389477

Clinical study of hydrazine sulfate in advanced cancer patients.

E Spremulli, G L Wampler, W Regelson.   

Abstract

Twenty-five patients with a variety of solid tumors were treated with hydrazine sulfate. Hydrazine was given orally in the form of 60 mg capsules from one to four times daily. No patient had a 50% reduction of tumor size. Subjective benefit was seen in three patients but it was of brief duration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 389477     DOI: 10.1007/bf00254983

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  PATHOLOGY AND TOXICOLOGY OF REPEATED DOSES OF HYDRAZINE AND 1,1-DIMETHYL HYDRAZINE IN MONKEYS AND RATS.

Authors:  R L PATRICK; K C BACK
Journal:  Ind Med Surg       Date:  1965-05

2.  Clinical trial of hydrazine sulfate in solid tumors.

Authors:  H J Lerner; W Regelson
Journal:  Cancer Treat Rep       Date:  1976-07

3.  Blood glucose levels and gluconeogenesis in animals bearing transplantable tumors.

Authors:  V S Shapot; V A Blinov
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

4.  Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy.

Authors:  J Gold
Journal:  Oncology       Date:  1974       Impact factor: 2.935

5.  Cancer cachexia and gluconeogenesis.

Authors:  J Gold
Journal:  Ann N Y Acad Sci       Date:  1974       Impact factor: 5.691

6.  Inhibition by hydrazine sulfate and various hydrazides, of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia.

Authors:  J Gold
Journal:  Oncology       Date:  1973       Impact factor: 2.935

7.  Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate.

Authors:  J Gold
Journal:  Oncology       Date:  1971       Impact factor: 2.935

8.  Proposed treatment of cancer by inhibition of gluconeogenesis.

Authors:  J Gold
Journal:  Oncology       Date:  1968       Impact factor: 2.935

9.  Trial of hydrazine sulfate (NSC-150014) in patients with cancer.

Authors:  M Ochoa; R E Wittes; I H Krakoff
Journal:  Cancer Chemother Rep       Date:  1975 Nov-Dec

10.  Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients.

Authors:  J Gold
Journal:  Oncology       Date:  1975       Impact factor: 2.935

View more
  3 in total

1.  Cancer-Associated Anorexia and Cachexia : Implications for Drug Therapy.

Authors:  C L Loprinzi; R M Goldberg; N L Burnham
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 2.  Is the pharmacological treatment of cancer cachexia possible?

Authors:  E Bruera
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

3.  Experience of the treatment with Sehydrin (Hydrazine Sulfate, HS) in the advanced cancer patients.

Authors:  V A Filov; M L Gershanovich; L A Danova; B A Ivin
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.